Yahoo
HKSE - Delayed Quote HKD

Biosino Bio-Technology and Science Incorporation (8247.HK)

2.975 0.000 (0.00%)
At close: October 22 at 2:13:38 PM GMT+8
Chart Range Bar
Loading chart for 8247.HK
  • Previous Close 2.975
  • Open 2.955
  • Bid 2.880 x --
  • Ask 2.975 x --
  • Day's Range 2.950 - 3.050
  • 52 Week Range 0.790 - 7.000
  • Volume 2,000
  • Avg. Volume 20,287
  • Market Cap (intraday) 430.504M
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.320
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date May 28, 2019
  • 1y Target Est --

Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China. The company offers clinical chemistry reagents, including single and double reagents, calibrators, QC products, and washing solution detergents; Elisa kits; rapid tests; and analyzers. It also provides medical and medical inspection services; and produces and sells medical instruments. Biosino Bio-Technology and Science Incorporation Guangdong has a strategic cooperation agreement with Xiaoshou Medical Technology Co., Ltd. The company was founded in 1988 and is based in Beijing, the People's Republic of China.

www.sinobio.com.cn

386

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

8247.HK
31.64%
HANG SENG INDEX (^HSI)
8.73%

1-Year Return

8247.HK
241.95%
HANG SENG INDEX (^HSI)
9.70%

3-Year Return

8247.HK
183.33%
HANG SENG INDEX (^HSI)
35.77%

5-Year Return

8247.HK
88.29%
HANG SENG INDEX (^HSI)
6.80%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -24.32%

  • Return on Assets (ttm)

    -7.49%

  • Return on Equity (ttm)

    -43.57%

  • Revenue (ttm)

    170.63M

  • Net Income Avi to Common (ttm)

    -41.5M

  • Diluted EPS (ttm)

    -0.320

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.26M

  • Total Debt/Equity (mrq)

    114.46%

  • Levered Free Cash Flow (ttm)

    21.6M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: